Andrea Necchi: Exploratory Biomarker Analyses of Adjuvant Nivolumab in Urothelial Carcinoma
Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared on X about a recent paper by Matthew D. Galsky et al. published on Nature Medicine:
“Exploratory biomarker analyses of adjuvant nivolumab in urothelial carcinoma from CheckMate274 trial are out in Nature Medicine Matt Galsky
- Pre-existing immune infiltration and T-cell infiltration is prognostic and predictive of adjuvant Nivolumab benefit
- Composite model development is the key to select those pts with high risk features who benefit the most from adjuvant Nivolumab
Integration of neoadjuvant therapy likely changes the immune context.
No one single periop trial is designed to quantify the contribution of components
Clinical trials addressing these concerns are lacking and desperately needed.”
Title: Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial
Authors: Matthew D. Galsky, Dean F. Bajorin, Yoshihiko Tomita, Dingwei Ye, Mads Agerbaek, Deborah Enting, Avivit Peer, Matthew Milowsky, Ko Kobayashi, Marc-Oliver Grimm, Frank Stenner, Justin M. David, Jun Li, Scott D. Chasalow, Federico Nasroulah, Abraham Apfel, Keziban Ünsal-Kaçmaz & Andrea Necchi
More posts featuring Andrea Necchi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023